NCT04060914

LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 225 (estimated)
• Sponsor: Beijing Anzhen Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The hypothesis in this study was that ticagrelor switched to 60 mg after 1 month of standard dose, with antiplatelet activity that is not inferior to the standard dose and better than 75 mg clopidogrel for patients with ACS after PCI.

Conditions

• Antiplatelet Therapy
• Coronary Artery Disease
• Percutaneous Coronary Intervention

Interventions

Type	Name	Description
DRUG	Ticagrelor 90mg	Ticagrelor 90 mg plus aspirin for 12 months
DRUG	Ticagrelor 90mg/60mg	1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
DRUG	Clopidogrel 75mg	Clopidogrel 75mg plus aspirin for 12 months

Timeline

• Start date: 2019-08-30
• Primary completion: 2020-12-30
• Completion: 2021-12-30
• First posted: 2019-08-19
• Last updated: 2019-08-19

Locations

1 site across 1 country: China